Boston Scientific (LTS:0HOY) LT-Debt-to-Total-Asset : 0.25 (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Boston Scientific LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Boston Scientific's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.25.

Boston Scientific's long-term debt to total assets ratio declined from Sep. 2023 (0.26) to Sep. 2024 (0.25). It may suggest that Boston Scientific is progressively becoming less dependent on debt to grow their business.

Boston Scientific LT-Debt-to-Total-Asset Historical Data

The historical data trend for Boston Scientific's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boston Scientific LT-Debt-to-Total-Asset Chart

Boston Scientific Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.29

0.31

0.29

0.26

Boston Scientific Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.26	0.26	0.27	0.25	0.25

Boston Scientific LT-Debt-to-Total-Asset Calculation

Boston Scientific's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	8961	/	35136
	=	0.26

Boston Scientific's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	9606	/	38078
	=	0.25

Boston Scientific (LTS:0HOY) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Boston Scientific LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Boston Scientific's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Boston Scientific Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Boston Scientific Corp (LTS:0HOY) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

BSX:USA BSX:Mexico 1BSX:Italy BSX:Germany BSX:Germany BSX:Germany B1SX34:Brazil BSXC:Austria

Address

300 Boston Scientific Way, Marlborough, MA, USA, 01752-1234

Website

https://www.bostonscientific.com

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Boston Scientific Headlines

No Headlines